Why the study?
Does a pentavalent inactivated rotavirus vaccine improve immunogenicity compared to an attenuated rotavirus vaccine in a mouse model?
Does a pentavalent inactivated rotavirus vaccine improve immunogenicity compared to an attenuated rotavirus vaccine in a mouse model?
Answers are grounded in this paper and cite their sources.
An alum-adjuvanted pentavalent inactivated rotavirus vaccine achieved protective IgG levels in a mouse model, suggesting potential as an alternative to attenuated vaccines.
There is a high demand for public immunization against Rotavirus (RV), especially in Africa. In Africa, the attenuated RV vaccination is contraindicated in patients with immune diseases and nutrition deficiency. Therefore, the inactivated RV vaccine (IRVV) could be an alternative. In this study, we aimed to develop a pentavalent-IRVV using the most circulating RV strains in Egypt and evaluate it against the commercially available Rotarix® vaccine. Trial-IRVV was developed with 5% sucrose, 2% polysorbate-80, and adsorbed on Alum to potentiate the vaccine immune response. Then, it was injected subcutaneously into mice groups at 0-, 21-, and 35-time intervals. In parallel, Rotarix was administered twice on 0 and 28th day. The success of the pentavalent-IRVV/monovalent-Rotarix vaccine immunity rested on achieving immunoglobulin G (IgG) exceeding 1:6,400 that implies less susceptibility to RV infection (RVI). IRVV stimulating IgG >1:6,400 could be an alternative vaccination approach to reach a reasonable protective immunization level against RVI. In addition, Alum adjuvant incorporation effectively provoked a triple elevation of the immunization pattern.
No takes yet. Share an insight, caveat, or question.
Hashim et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: